| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ... Annals of Oncology 20 (1), 117-120, 2009 | 577 | 2009 |
| Emerging treatment strategies for COVID-19 infection M Gavriatopoulou, I Ntanasis-Stathopoulos, E Korompoki, D Fotiou, ... Clinical and experimental medicine 21, 167-179, 2021 | 366 | 2021 |
| Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone E Kastritis, A Anagnostopoulos, M Roussou, S Toumanidis, C Pamboukas, ... Haematologica 92 (10), 1351-1358, 2007 | 233 | 2007 |
| Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease E Kastritis, E Terpos, L Moulopoulos, M Spyropoulou-Vlachou, ... Leukemia 27 (4), 947-953, 2013 | 199 | 2013 |
| Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors MA Dimopoulos, M Roussou, M Gavriatopoulou, F Zagouri, M Migkou, ... Clinical Lymphoma and Myeloma 9 (4), 302-306, 2009 | 158 | 2009 |
| Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of … MA Dimopoulos, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ... Leukemia 24 (10), 1769-1778, 2010 | 148 | 2010 |
| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Cancer Journal 11 (8), 138, 2021 | 127 | 2021 |
| Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens M Roussou, E Kastritis, M Migkou, E Psimenou, I Grapsa, C Matsouka, ... Leukemia & lymphoma 49 (5), 890-895, 2008 | 113 | 2008 |
| Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents M Roussou, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ... Leukemia research 34 (10), 1395-1397, 2010 | 111 | 2010 |
| Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients … LA Moulopoulos, MA Dimopoulos, E Kastritis, D Christoulas, ... American journal of hematology 87 (9), 861-864, 2012 | 109 | 2012 |
| Cardiac and renal complications of carfilzomib in patients with multiple myeloma MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, D Ziogas, ... Blood advances 1 (7), 449-454, 2017 | 101 | 2017 |
| Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure … MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, ... American journal of hematology 91 (5), 499-502, 2016 | 101 | 2016 |
| Dickkopf-1: a suitable target for the management of myeloma bone disease M Gavriatopoulou, MA Dimopoulos, D Christoulas, M Migkou, M Iakovaki, ... Expert opinion on therapeutic targets 13 (7), 839-848, 2009 | 95 | 2009 |
| Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma E Kastritis, E Terpos, M Roussou, M Gavriatopoulou, M Migkou, ... Haematologica 102 (3), 593, 2017 | 94 | 2017 |
| Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications O Nicolatou-Galitis, M Migkou, A Psyrri, A Bamias, D Pectasides, ... Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 113 (2), 234-238, 2012 | 94 | 2012 |
| Treatment of light chain deposition disease with bortezomib and dexamethasone E Kastritis, M Migkou, M Gavriatopoulou, P Zirogiannis, ... Haematologica 94 (2), 300, 2009 | 92 | 2009 |
| Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment MA Dimopoulos, D Christoulas, M Roussou, E Kastritis, M Migkou, ... European journal of haematology 85 (1), 1-5, 2010 | 89 | 2010 |
| Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents LA Moulopoulos, MA Dimopoulos, D Christoulas, E Kastritis, ... Leukemia 24 (6), 1206-1212, 2010 | 80 | 2010 |
| Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies E Kastritis, M Roussou, M Gavriatopoulou, M Migkou, D Kalapanida, ... American journal of hematology 90 (4), E60-E65, 2015 | 64 | 2015 |
| Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy E Kastritis, M Gavriatopoulou, M Roussou, M Migkou, D Fotiou, DC Ziogas, ... American journal of hematology 92 (7), 632-639, 2017 | 63 | 2017 |
